Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + Pembrolizumab in PD-L1+ NSCLC
NCT04139317Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Progression-Free Survival at 1.3 years. Started Jan 2020; status: terminated.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04139317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139317.